Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum Build info

Synonyms

  • ENCEPHALOPATHY AUTOIMMUNE EVAL, S
  • ENS2
  • ENCEPHALOPATHY AUTOIMMUNE EVAL, S
  • LAB10600

Short Name

ENCEPHALOPATHY AUTOIMMUNE EVAL, S

Procedure Master Number

LAB10600

Procedure ID

111704

Clinical Info

Mayo code ENS2
Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in serum specimens

The following accompaniments should increase of suspicion for autoimmune encephalopathy:
-Headache
-Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Inflammatory cerebral spinal fluid (or isolated protein elevation)
-Neuroimaging signs suggesting inflammation

Evaluating limbic encephalitis (noninfectious)

Directing a focused search for cancer

Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect

Specimen Type

Blood

Container

Red Top Tube

Collection Instructions

Container/Tube: Gold Top or Red Top Tube
Specimen: 4.0 mL serum (2.5 mL min)

Patient Preparation:
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.

Transport Instructions

Refrigerated

Specimen Stability

72 Hours Room Temperature
28 Days Refrigerated or Frozen

Methodology

Indirect Immunofluorescence Assay (IFA)
Cell-Binding Assay (CBA)
Western Blot (WB)
Immunoblot (IB)
Radioimmunoassay (RIA)

Days Performed

TAT: 9-13 Days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT

86255 x 23
86341
LOINC Code: 94697-0

PDM

1759374

Results
Component Name Base Name Common Name External Name
AGNA-1, S AGNA1S AGNA 1 S Agna-1, S
AMPA-R ABCBA AMPARABCBA AMPA R ABCBA Ampa-R Abcba
AMPHIPHYSIN AB, S AMPHIPABS AMPHIP AB S Amphiphysin Ab, S
ANNA-1, S ANNA1S ANNA 1 S Anna-1, S
ANNA-2, S ANNA2S ANNA 2 S Anna-2, S
ANNA-3, S ANNA3S ANNA 3 S Anna-3, S
CASPR2-IGG CBA, S CASPR2IGCBAS CASPR2 IGG CBA S Caspr2-Igg Cba, S
CRMP-5-IGG WESTERN BLOT CR5IGWESBLOT CR 5 IGG WES BLOT Crmp-5-Igg Western Blot
DIPEPTIDYL AMINOPEPTIDASE-LIKE PROTEIN 6 AB IGG DPPXABIFA DIPEPTIDYL AMINOPEPTIDASE LIKE PROTEIN 6 AB IGG Dipeptidyl aminopeptidase-like protein 6 AB IGG
ENCEPHALOPATHY, INTERPRETATION, S ENCEPINTRPS ENCEP INTERP S Encephalopathy, Interpretation, S
GABA-B- RECEPTOR ANTIBODY BY CBA, SERUM GABABABCBA GABA B ABCBA Gaba-B- Receptor Antibody By Cba, Serum
GLIAL FIBRILLARY ACIDIC PROTEIN.ALPHA SUBUNIT AB IGG GFAPIFA GLIAL FIBRILLARY ACIDIC PROTEIN ALPHA SUBUNIT AB IGG Glial Fibrillary Acidic Protein.Alpha Subunit Ab Igg
GLUTAMIC ACID DECARBOXYLASE ANTIBODY GADAB GLUTAMIC ACID DECARB AB
IFA NOTES IFANOTES IFA NOTES Ifa Notes
LGI1-IGG CBA, S LGI1IGGCBAS LGGI1 IGG CBA S Lgi1-Igg Cba, S
METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG MGLUR1ABIFA METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG Metabotropic glutamate receptor 1 AB IGG
NEUROCHONDRIN AB NEUROCHIFA NEUROCHONDRIN AB Neurochondrin AB
NEUROCHONDRIN IFA, CSF NEURCHAB NEUROCHONDRIN IFA, CSF Neurochondrin Ifa, Csf
NEURONAL (V-G) K+ CHANNEL AB, S VGKCHANAB NEURONAL VOLTAGE GATED K CHANNEL AB Neuronal (V-G) K+ Channel Ab, S
NIF IFA, CSF NIFIFA NIF IFA, CSF Nif Ifa, Csf
NMDA-R AB CBA, CSF NMDARABCBA NMDA R AB CBA, CSF Nmda-R Ab Cba, Csf
NMDA-R ABCBA NMDARABCBA NMDA R ABCBA Nmda-R Abcba
NMDAR- ABCBAC NMDARABCBAC NMDAR ABCBAC NMDAR- AbCBAC
PCA-1, S PCA1S PCA 1 S Pca-1, S
PCA-2, S PCA2S PCA 2 S Pca-2, S
PCA-TR, S PCATRS PCA TR S Pca-Tr, S
PURKINJE CELL CYTOPLASMIC AB TYPE 1 PURCYTO1 PURKINJE CELL CYTOPLASMIC AB TYPE 1 Purkinje Cell Cytoplasmic Ab Type 1
PURKINJE CELL CYTOPLASMIC AB TYPE 2 PURCYTO2 PURKINJE CELL CYTOPLASMIC AB TYPE 2 Purkinje Cell Cytoplasmic Ab Type 2
REFLEX ADDED REFADD REFLEX ADDED Reflex Added